Basilea and Astellas shake hands on antifungal deal worth up to CHF550 million
This article was originally published in Scrip
Executive Summary
Swiss biotech company Basilea Pharmaceutica has agreed a worldwide licensing deal with Astellas Pharma for its Phase III antifungal isavuconazole.